U.S. Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Global Market
Related Markets
U.S. glp-1 agonists weight loss drugs market highlights
- The U.S. glp-1 agonists weight loss drugs market generated a revenue of USD 15,392.9 million in 2025 and is expected to reach USD 50,939.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 13.97% from 2026 to 2033.
- In terms of segment, semaglutide (wegovy) was the largest revenue generating drug in 2025.
- Tirzepatide (Zepbound) is the most lucrative drug segment registering the fastest growth during the forecast period.
Glp-1 agonists weight loss drugs market data book summary
| Market revenue in 2025 | USD 15,392.9 million |
| Market revenue in 2033 | USD 50,939.1 million |
| Growth rate | 13.97% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (wegovy) |
| Fastest growing segment | Tirzepatide (Zepbound) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Wegovy), Tirzepatide (Zepbound), Liraglutide (Saxenda), Other Drugs |
| Key market players worldwide | Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S ADR, Viking Therapeutics Inc, Structure Therapeutics |
Other key industry trends
- In terms of revenue, U.S. accounted for 73.8% of the global glp-1 agonists weight loss drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. glp-1 agonists weight loss drugs market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 50,939.1 million by 2033.
In the U.S., the GLP-1 agonists weight loss drugs market leads North America, capturing 95.23% of the regional market share in 2024.
Semaglutide and Tirzepatide have gained significant popularity due to their effectiveness in weight loss, with widespread distribution through hospital pharmacies and retail pharmacies. Additionally, the oral formulations of these drugs are gaining traction, making them more accessible to a broader patient base.
No credit card required*
Publish Date: Feb 03, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Agonists Weight Loss Drugs Market Scope
GLP-1 Agonists Weight Loss Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Structure Therapeutics | View profile | 101-250 | South San Francisco, California, United States, North America | structuretx.com/ |
| Eli Lilly and Company | View profile | - | - | - |
U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Agonists Weight Loss Drugs Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Wegovy) was the largest segment with a revenue share of 79.76% in 2025.
Horizon Databook has segmented the U.S. glp-1 agonists weight loss drugs market based on semaglutide (wegovy), tirzepatide (zepbound), liraglutide (saxenda), other drugs covering the revenue growth of each sub-segment from 2021 to 2033.
In the U.S., the GLP-1 agonists weight loss drugs market leads North America, capturing 95.23% of the regional market share in 2024.
Semaglutide and Tirzepatide have gained significant popularity due to their effectiveness in weight loss, with widespread distribution through hospital pharmacies and retail pharmacies. Additionally, the oral formulations of these drugs are gaining traction, making them more accessible to a broader patient base.
- U.S. Glp-1 Agonists Weight Loss Drugs Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Wegovy)
- Liraglutide (Saxenda)
- Tirzepatide (Zepbound)
- Other Drugs
- U.S. Glp-1 Agonists Weight Loss Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Parenteral
- Oral
- U.S. Glp-1 Agonists Weight Loss Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Retail Pharmacies
- Hospital Pharmacies
- Other Pharmacies
Reasons to subscribe to GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Our clientele includes a mix of GLP-1 Agonists Weight Loss Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Glp-1 Agonists Weight Loss Drugs Market, 2021-2033 (US$M)
U.S. glp-1 agonists weight loss drugs market statistics, by drug, 2021-2033 (US$M)
